Biogen Posts A $0.14 Per-Share Loss On RayThera Deal Charge As Growth Drugs Climb 49%
Revenue rose 11% to $2.8 billion, and the company lifted the low end of its 2026 adjusted EPS outlook to $12.20.
Biogen, the biopharmaceutical company focused on neurology, specialized immunology and rare diseases, swung to a loss of $0.14 per share in the third quarter, from a $3.17 profit a year earlier, in results released Wednesday. Transaction-related charges drove the loss, while revenue grew 11% to $2.8 billion.
Growth drugs offset the MS slide
Biogen's growth portfolio brought in $1.26 billion, up 49% from a year earlier and 63% of core pharmaceutical revenue. The quarter was the first full one with the Apellis products, which Biogen bought when the deal closed in May 2026.
Spinraza led rare disease at $461 million, up 23%, and the company said the shift to a high-dose regimen continues to exceed its expectations. Leqembi, recorded by partner Eisai, reached $202 million, up 67%. Syfovre rose 27% to $191 million, and Empaveli rose 92% to $52 million. Skyclarys climbed 34% to $178 million.
Multiple sclerosis revenue fell 13% to $919 million. Vumerity slid 11% to $192 million, which the company blamed mainly on U.S. formulary dynamics. Rare disease revenue rose 27% to $676 million, and biosimilars fell 16% to $166 million.
CEO Christopher A. Viehbacher said the results show that "Biogen has returned to growth."
Where the loss came from
Adjusted earnings were $2.62 per share, down from $4.81. The quarter carried $284 million of acquired research, upfront and milestone expense, mostly for the RayThera purchase, against $2 million a year earlier.
Other costs also rose. Research and development spending was $574 million, up from $436 million, and selling, general and administrative costs were $752 million, up from $595 million, both reflecting Apellis. Net interest expense on Apellis debt also weighed on the adjusted figure. The standard-accounting tax rate was negative 128.5% because the RayThera charge is not deductible.
Free cash flow was about $600 million, after roughly $40 million of capital spending. Biogen ended September with about $1.3 billion in cash and about $7.7 billion in debt.
Guidance and the December readout
Biogen raised the low end of its 2026 adjusted EPS range to $12.20–$13.00, from $12.00–$13.00. It cited business strength and lower-than-expected Apellis dilution, and still expects revenue to grow by a mid-single-digit percentage.
Top-line data from two late-stage lupus trials of litifilimab are due in the first half of December 2026.
Biogen expects top-line data from both late-stage litifilimab lupus trials, TOPAZ-1 and TOPAZ-2, in the first half of December 2026.
Sources
- 8-K Filing — BIOGEN INC. (BIIB) — SEC EDGAR
- Exhibit exhibit991-q32026pressrele.htm — BIOGEN INC. 8-K exhibit — SEC EDGAR
- Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat? — Yahoo Finance